Hi Steini,
Thanks for the info. Looking at the response you received, I'm clearly missing something here, but are you sure that your source is reliable?
The HSV-2 phase II clinical study is already fully funded and without any intention of the Company to secure partnership funding for alleviating any of the cost burden associated with the global roll-out strategy of CardioCel, current cash in bank together with any beefed up sales revenue from CC over the short term certainly ain't gonna cut it.
Who's going to finance the clinical study programs for the additional ADAPT Products under development, who's going to continue funding the scale-up manufacturing and support, and cover all the other upfront high costs associated with the additional sales, marketing, R&D, clinical, and regulatory resources required for the current global roll-out strategy of CC?
But, why exactly when they already hold a controlling ownership interest?
I must be missing something - further thought appreciated
- Forums
- ASX - By Stock
- AVR
- Ann: Trading Halt
Ann: Trading Halt, page-133
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M |
Open | High | Low | Value | Volume |
$11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100 | $11.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.22 | 127 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100 | 11.700 |
1 | 500 | 11.600 |
1 | 1000 | 11.560 |
2 | 270 | 11.000 |
1 | 25 | 10.990 |
Price($) | Vol. | No. |
---|---|---|
12.220 | 127 | 1 |
12.240 | 2300 | 1 |
12.250 | 160 | 1 |
12.400 | 500 | 1 |
12.500 | 429 | 1 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |